Edward Snowden Warned About Genome Editing With CRISPR-Cas9

By The Patriots
Profile image

Edward Snowden Warned About Genome Editing With CRISPR-Cas9

Genome Editing with CRISPR-Cas9

Attorney Tom Rense has just released information that Pfizer and Moderna have developed a Messenger RNA capable of surviving the digestion process which permits vaccination materials to be in the food supply for both humans and cattle.

What You Eat Affects Your Genes: RNA from Rice Can Survive Digestion and Alter Gene Expression

Messenger RNA is also capable of being transmitted in the air. Beware of aerosol sprays! : Engineers create an inhalable form of messenger RNA

For those of you who have never heard of human Gene editing watch this YouTube video to gain a basic understanding of what it can do. Also recognize these madmen are going to implement their so-called ‘evolutionary enhancement plan’ to destroy the notion of man being created in the image of God to one being created in the monster SATAN”S image.

For those of you who have never heard of human Gene editing watch this YouTube video to gain a basic understanding of what it can do. Also recognize these madmen are going to implemnt their so-called ‘evolutionary enhancement plan’ to destroy the notion of man being created in the image of God to one being created in the monster SATAN”S image.

Edward Snowden is the one who first revealed this technology along with information that these same organizations (Facebook,Twitter Et Al) were spying on Americans. Time to recognize that there will be no escape except through GOD. Time to repent and follow him while you still can. Are you beginning to understand the bible’s warning of “perilous times shall come in the last days” yet?

Pfizer Used Dangerous Assumptions, Rather than Research, to Guess at Outcomes

by Robert W. Chandler, M.D., M.B.A. - Team 5

At the launch of widespread mass inoculation of the public with Pfizer’s mRNA vaccine, BNT162b2, media, physicians’ spokespeople,  and government officials communicated widely that the injected drug would be retained at the injection site muscle tissue and in local lymph nodes. The components were supposed to be metabolized in a day or so, leaving only induced SARS CoV-2 Spike antigen to evoke a therapeutic immune response. A short pulse of drug effect would be followed, they claimed, by limited production of Spike antigen.

However, newly released internal Pfizer documents show that this is not true.  In fact, the injection causes widespread distribution of the material in tissues and this distribution persists for at least two days, and probably much longer. These facts are the exact opposite of what was publicized.

A cluster of FDA-released Pfizer documents — “Final Report: A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats”[https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_185350.pdf], 2.4 NONCLINICAL OVERVIEW [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_24_nonclinical-overview.pdf], “MODULE 2.6.5. PHARMACOKINETICS TABULATED SUMMARY”

[https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_26_pharmkin-tabulated-summary.pdf] and the heavily redacted  report “R&D STUDY REPORT No. R-20-0072 – EXPRESSION OF LUCIFERASE-ENCODING MODERNA AFTER I.M. APPLICATION OF GMPREADY ACUITAS LIPID NANOPARTICLE FORMULATION “[https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_R-20-0072.pdf] — all examine tissue distribution of Pfizer’s mRNA vaccine BNT162b2. These documents will be addressed in this report. 

Pfizer Study 185350,” Final Report: A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rat”, is one of 21 preclinical Prizer studies involving mice, rats and rhesus macaque non-human primates. Study No. 185350 (Sponsor Reference ALC-NC-0552) was summarized in Pfizer’s “2.4 Nonclinical Overview” and was separately published as a Final Report dated September 24, 2020.

Contained in that document is the following identification of the source:

Test Facility Study No. 185350 REDACTED

SPONSOR: Acuitas, 

6190 Agronomy Road, 

Ste. 402, 

Vancouver, V6T 1Z3 Canada

Sponsor Reference No. ALC-NC-0552

This study was made up  of 42 male and 21 female Wistar Han rats. These rats were injected with 50 or 100 micrograms of BNT162b2 mRNA/LNP (lipid nanoparticle) product labelled with a radioactive tracer material, 3H. Then the rats were sacrificed at intervals of 0.25 hours (15 minutes); 1 hour; 2 hours; 4 hours; 8 hours; and then at 1 and 2 days.

The results of 21 male and 21 female sacrificed rats are presented.

The 100-microgram dose was associated with loss of weight and apparent toxicity in two animals. Unfortunately, the full results of the 100-microgram dose were not presented at all. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_185350.pdf, p. 11.]

animal group

This is very important. The 100 microgram dose was considered too toxic to continue to use in the experiment, so the dosage was cut in half. 100 micrograms is the amount in the Moderna injections.

The 50 microgram dose was not safe. One female rat in the 50-microgram dose exhibited piloerection and hunched posture. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_185350.pdf, p.19.]

The injection did not stay at the injection site, as we were promised it would. Rather, following injection, the drug was persistent at the injection site, with a third of the dose remaining in muscle tissue for two days in males, and a sixth of the dose remained in females for the same duration.

 injection site

But it did not all stay in the deltoid muscle. From the injection site in the deltoid muscle, mRNA/ Lipid Nanoparticles appeared in blood and plasma fifteen minutes after injection and persisted for the entire duration of the two-day study.

On page 20 of “Final Report: A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rat,” the authors note that widespread distribution to “most tissues” occurs by the time of first analysis at 15 minutes after injection. 

There was greater accumulation in blood when compared to plasma, and males generally had higher concentrations than females with lower blood to plasma ratios. No explanation for these differences was offered. 

The major tissues that contained the drug concentration, aside from muscle at the injection site, were identified as being the liver, spleen, adrenal glands, and ovaries. The drug persisted in tissues throughout the duration of the study. The meaning and potential implications of the persistence in tissues was not addressed. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_185350.pdf, p. 21.]

Top: highest mean concentrations. Bottom: equivalent % dose.

The next two tables present the overall tissue distribution data from this study. It is reasonable to conclude, thus, that BNT162b2 is distributed throughout the body and persists for at least two days, the duration of the study. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_185350.pdf, pp. 7-8.] Tissue specimens were harvested but, unfortunately, no microscopic analysis of these specimens is presented at all, so potential damage to various organs was not evaluated.

A separate pharmacokinetic study, “PF-07302048,” looked at the persistence of the LNP (lipid nanoparticle) transport vessel with a test mRNA inside consisting of LNP coating wrapped around Luciferase mRNA, Figure 2.4.3-1 below. [“R&D STUDY REPORT No. R-20-0072 – EXPRESSION OF LUCIFERASE-ENCODING MODRNA AFTER I.M. APPLICATION OF GMPREADY ACUITAS LIPID NANOPARTICLE FORMULATION”, https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_R-20-0072.pdf.]

The object of this study was to follow the LNP vessel in plasma and liver, and then measure transcription of mRNA inside target organs to validate the delivery model using the bioluminescent properties of Luciferase to identify transcription of the mRNA in target tissues. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M4_4223_R-20-0072.pdf

From this study, we learn that the two measured components of the lipid nanoparticle coating, ALC-0315 [(4-hydroxybutyl) azanediyl]di(hexane-6, 1-diyl) bis (2-hexyldecanooate)] and ALC-0159 (2-[2-(polyethylene glycol)-2000]-N, N-ditetradecylacetamide) are detectable in plasma after 300 hours – that is to say, 12.5 days – which fact raises the issue of how long the contents of the LNP vessel with the mRNA inside persists, and what the implications are of prolonged occupation of host cells by this material. In this study, the BNT162b2 was injected intravenously, accelerating the dissemination of drug. [2.4 NONCLINICAL OVERVIEW, https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_24_nonclinical-overview.pdf, p.16.]


This study of the biodistribution of the LNP coating containing Luciferase mRNA found that not only was the mRNA transcribed, but the LNP “vessel” components ALC-0315 and ALC-0159 were retained in the liver and in the plasma for at least 12.5 days. The fate of the Luciferase mRNA was not discussed.

With respect to degradation of the mRNA component, we learn from “2.4 Nonclinical Overview” that Pfizer/Acuitas did not study at all the degradation of the synthetic mRNA in BNT162b2. Similarly, there was no analysis by Pfizer of protein products from BNT162b2 provided. [https://www.phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_24_nonclinical-overview.pdf, p.20.]

Liver, Spleen, Adrenal glands and Ovaries take up increasing amounts of drug compared with other organs as drug is transported from the injection site by blood and plasma. These data were generated during the 48 hours after injection and these four organs were still accumulating the transferred drug as the experiment ended. Looking at the tissue concentration shown on the y axis, there is 165 microgram lipid equivalent/g drug remaining at the injection site compared with 24 microgram lipid equivalent/g in the liver. This indicates that there may be continued transport from the injection site by blood and plasma well beyond 48 hours when the last animals were sacrificed.

The remaining plots show patterns of drug distribution by blood and plasma and accumulation in organs. Page 1 lists the table of values following injection of radioactive labeling of the LNP component of BNT162b2. Pages 2-16 are plots of drug in Adrenal glands, Bone marrow, Brain, Heart, Kidneys, Liver, Lung, Lymph nodes mandibular and mesenteric, Ovaries, Spleen, Thyroid, Blood and Plasma, Injection site, mandibular lymph nodes vs. mesenteric, and organs with greatest concentrations of the drug.
BNT162b2 has lipid nanoparticles that may have adverse effects on organs and tissues from the lipid component as well as from the mRNA and Spike proteins produced by the mRNA.

Graphical representation of the Pfizer data set allows the reader to get a better understanding of how BNT162b2 flows from the injection site to body organs.
For example, this chart is a plot of tissue concentration first rising steeply at the injection site, left chart, then peaks and declines as the organ systems accumulate concentrations of drug more slowly early then rise over time, right chart.

The final chart on page 19 contrasts ovaries vs testes with approximately 38 times more drug concentration of drug in ovaries. More work is needed to see if there is a connection between menstrual cycle changes as have been reported by Lee, et. al. and elsewhere.


Similarly, although the data is incomplete with known outcome in only 27 of 270 pregnancy cases as reported in Pfizer document 5.3.6, the first three months of Adverse Events reporting following widespread release after an Emergency Use Authorization was given by the FDA. What data does exist is disconcerting.


 Several serious questions are raised by these results:

  1. How long does the BNT162b2 mRNA persist in human tissues? Where does it go in the host cell? How long does it persist inside the cell? What proteins does it produce, and for how long?
  2. Is there any possibility that the BNT162b2 mRNA can be transcribed into DNA, then incorporate into the host genome? If this happens what are the implications?
  3. What are the toxicities from the lipid nanoparticle coating?
  4. Was Pfizer obligated to answer these questions prior to human testing?
  5. Doesn’t proper informed consent require answers to these questions?

Fortunately, answers to these important questions are beginning to appear:

1a. Duration of mRNA in tissues:

In a July 19, 2022, article, the essayist Joomi reviews the topic of how long BNT162 b2 containing mRNA stabilized by a synthetic nucleotide 1N-methyl pseudouridine persists in human tissues. [https://joomi.substack.com/p/were-still-being-misled-about-how?r=chkp3&s=r&utm_campaign=post&utm_medium=web]

A January 2022 human lymph node biopsy study from Stanford University found that the mRNA from both Pfizer and Moderna persists for at least two months, which was the duration of the study. [https://www.cell.com/action/showPdf?pii=S0092-8674%2822%2900076-9]

1b. Proteins produced from BNT162b2 mRNA:

Spike protein is produced after the mRNA is transcribed, and has been found in vivo for at least four months after inoculation. [https://joomi.substack.com/p/were-still-being-misled-about-how?r=chkp3&s=r&utm_campaign=post&utm_medium=web]

Proteins transcribed from the mRNA have not been completely characterized yet. SARS-CoV-2-like Spike protein has been identified as long as four months after inoculation with LNP/mRNA in human exosomes. Toxicity of Spike protein has been described and is reviewed in  the essay “We’re still being misled about how long the mRNA vaccines last in the body.” [https://joomi.substack.com/p/were-still-being-misled-about-how?r=chkp3&s=r&utm_campaign=post&utm_medium=web]

2. What is the fate of BNT162b2 mRNA?

We were informed that “RNA is required for protein synthesis, does not integrate into the genome, is transiently expressed, and is metabolized and is eliminated by the body’s natural mechanisms and, therefore is considered safe.” [Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomized, prospective, first-in-human phase 1 clinical trial. Lancet 90, 1511-1520 (2017).] [Sahin, U. e al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222-226 (2017).]

However, Alden, et. al., reporting in Current Issues in Molecular Biology 2022, 44, 1115-1126, found BNT162b2 mRNA is reverse transcribed into host DNA beginning six hours after contact with BNT162b2:

“In the BNT162b2 toxicity report, no genotoxicity nor carcinogenicity studies have been provided. Our study shows that BNT162b2 can be reverse transcribed to DNA in liver cell line Huh7, and this may give rise to the concern if BNT162b2-derived DNA may be integrated into the host genome and affect the integrity of genomic DNA, which may potentially mediate genotoxic side effects. At this stage, we do not know if DNA reverse transcribed from BNT162b2 is integrated into the cell genome. Further studies are needed to demonstrate the effect of BNT162b2 on genomic integrity, including whole genome sequencing of cells exposed to BNT162b2, as well as tissues from human subjects who received BNT162b2 vaccination.” [https://www.mdpi.com/1467-3045/44/3/73/htm

This study did not identify DNA transcribed from BNT162b2 mRNA in the host genome following transcription.

However, Zhang et. al., working at Massachusetts Institute of Technology, demonstrated fragments of SARS-CoV-2 mRNA integrated in host DNA in “Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,” published in 2021 in PNAS, vol. 118, no. 21:

“We show here that SARS-CoV-2 RNA can be reverse-transcribed and integrated into the genome of the infected cell and be expressed as chimeric transcripts fusing viral with cellular sequences. Importantly, such chimeric transcripts are detected in patient-derived tissues.” [https://www.pnas.org/doi/10.1073/pnas.2105968118]

So, scientists are getting close to knowing whether BNT162b2, with its synthetic mRNA, is translated into host DNA and is now a permanent part of human genetic material. If so, the next step is to determine what the implications are.

3. What are the toxicities from the lipid nanoparticle coating?

More research is required to understand the implications of LNP concentration in various organ tissues. It is thought that the PEG component (the polyethylene glycol that coats the LNP) is responsible for anaphylaxis, an often rapid-onset major physiologic event that requires emergency treatment.

4. Was Pfizer obligated to answer these questions prior to human testing?
5. Doesn’t proper informed consent require answers to these questions?

The answers to questions 4 and 5 are “yes,” and the reasons should be obvious now. Basic information about functioning of this mRNA product, BNT162b2, was not known at the time of mass inoculation; and, therefore, a proper risk, benefits and complications discussion was compromised by lack of information. Informed consent is not possible in such a situation.

In conclusion, many negatively consequential shortcuts were made in the development of BNT162b2.

Many omissions in basic research evaluation of BNT162b2 were kept hidden, and there was outright misinformation regarding some of the work that was done.

Assumptions rather than actual research to determine where BNT162b2 goes, what it does, and how long it lasts were made that proved to be false and constitute intentional mis/dis/mal information. We were told that the prodrug, BNT162b2, consisting of a lipid nanoparticle coating of synthetic messenger ribonucleic acid (modRNA), would be deposited in muscle tissue at the injection site and would be migrate to local lymphatics prior to rapid degradation producing Spike antigens for a limited period of time that would produce a desired immune response.

However, Pfizer in its very early Phase 1 trial with mice, rats, and rhesus non-human primates learned that the LNP/mRNA is rapidly disseminated throughout the body and remained in tissues for as long as it was studied, 48 hours for BNT162b2 and 12.5 days for the LNP/Luciferase mRNA test product.

No effort was expended to determine what proteins are produced by the modRNA, what their physiological actions are and how long they are produced as well as what toxicities and adverse events might be anticipated with widespread usage of the LNP/mRNA prodrug.

FOIA requests for internal documents from federal health care agencies, independent review board members, approximately 140 clinical investigators and Pfizer personnel should be made.

Billions of doses were administered to billions of p

eople. The scale of this potentially massive medical misstep is large.

Ten months to develop novel gene therapy for a novel virus is well short of the five to 10 years usually required to develop, test and refine such a product. After billions of doses have been given to children and adults around the world, possibly altering the course of human evolution, the public is now seeing the unfortunate consequences of cutting corners.

This Report was written exclusively for DailyClout by the Members of the War Room / DailyClout Pfizer Documents Research Volunteers.

It should not be copied or republished without permission from DailyClout or a full credit and link to DailyClout.io